Clinical trial
Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT06331624 is registered in ClinicalTrials.gov with GRI Bio Operations, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- GRI Bio Operations, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 24, 2024
- Completion date
- September 30, 2025
- Enrollment
- 35 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.